1. Home
  2. NSPR vs MIRA Comparison

NSPR vs MIRA Comparison

Compare NSPR & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InspireMD Inc.

NSPR

InspireMD Inc.

HOLD

Current Price

$0.50

Market Cap

38.9M

Sector

Health Care

ML Signal

HOLD

Logo MIRA Pharmaceuticals Inc.

MIRA

MIRA Pharmaceuticals Inc.

HOLD

Current Price

$0.71

Market Cap

32.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NSPR
MIRA
Founded
2005
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.9M
32.1M
IPO Year
2009
2023

Fundamental Metrics

Financial Performance
Metric
NSPR
MIRA
Price
$0.50
$0.71
Analyst Decision
Buy
Analyst Count
3
0
Target Price
★ $3.33
N/A
AVG Volume (30 Days)
69.0K
★ 164.1K
Earning Date
11-03-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ N/A
Revenue
★ $2,310,000.00
N/A
Revenue This Year
$9.14
N/A
Revenue Next Year
$105.44
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.50
$0.60
52 Week High
$2.50
$2.45

Technical Indicators

Market Signals
Indicator
NSPR
MIRA
Relative Strength Index (RSI) 17.89 39.69
Support Level N/A $0.60
Resistance Level $1.00 $0.82
Average True Range (ATR) 0.07 0.07
MACD -0.02 -0.02
Stochastic Oscillator 3.12 28.12

Price Performance

Historical Comparison
NSPR
MIRA

About NSPR InspireMD Inc.

InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.

About MIRA MIRA Pharmaceuticals Inc.

Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.

Share on Social Networks: